|
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A 2bp deletion in exon 6 of CHRFAM7A, which disrupts the hybrid gene and has previously been associated with P50 deficit, was genotyped in 251 individuals from the Maudsley Family Study of schizophrenia.
|
17012698 |
2006 |
|
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A CHRNA7 genotype associated with schizophrenia was correlated with diminished P50 inhibition in the placebo-treated infants, but not in the choline-treated infants.
|
23318559 |
2013 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A deficit in sensory gating measured by the suppression of P50 auditory event-related potential (ERP) has been implicated in the biological bases of schizophrenia and some other psychiatric disorders and proposed as a candidate endophenotype for genetic studies.
|
17014995 |
2007 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A deficit in the inhibition of the P50 evoked response to repeated auditory stimuli has been characterized as a neurobiological deficit in schizophrenia.
|
10813805 |
2000 |
|
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A number of studies have suggested that the alpha-7-nicotinic receptor D15S1360 polymorphism is associated with schizophrenia and a deficiency in the normal inhibition of the P50 auditory-evoked response.
|
15100704 |
2004 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A paired-stimulus auditory event- related potential paradigm was used to examine P50 sensory gating in 85 schizophrenia patients (56 medicated with typical antipsychotics and 29 unmedicated), 83 of their first-degree relatives (46 parents and 37 siblings), and 29 normal comparison subjects.
|
12450949 |
2002 |
|
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Abnormality in the P50 auditory-evoked potential gating is an endophenotype associated with schizophrenia.
|
12399955 |
2002 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, we observed no P50 suppression deficit in those EOP patients diagnosed with schizophrenia (N = 39).
|
31649298 |
2020 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adult-onset schizophrenia is generally associated with one parent who demonstrates abnormal P50 sensory gating and elevated anticipatory saccades and one parent who is normal on the physiologic measures (i.e., unilineal inheritance).
|
10206241 |
1999 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
All four event-related potential indices are potentially valid endophenotypes for schizophrenia, but P50 suppression and P300 amplitude show the closest genetic relationship to schizophrenia.
|
17475740 |
2007 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
As suggested by several studies, abnormal sensory gating measured by the P50 paradigm could be an endophenotype predisposing to schizophrenia.
|
14569275 |
2004 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associated with alpha 7 nicotinic acetylcholine receptor (α7 nAChR) dysfunction and shown to be improved with nicotine and α7 nAChR agonists, SG has recently been shown to be improved in low P50 suppressing SCZ patients following acute CDP-choline treatment.
|
30920339 |
2019 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Auditory P50 sensory gating deficits correlate with genetic risk for schizophrenia and constitute a plausible endophenotype for the disease.
|
20102668 |
2011 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Auditory P50 gating and hippocampal volume were measured in 16 male and 15 female patients with schizophrenia.
|
30862179 |
2019 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because P50 sensory gating deficit is a common neurophysiological dysfunction in patients with schizophrenia and schizophrenia spectrum disorders, it is conceivable to hypothesize that the human alpha7 neuronal nicotinic receptor subunit gene might be a susceptible gene for schizophrenia.
|
15531077 |
2004 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deficits in P50 suppression have high heritability and show linkage to the alpha-7 subunit of the nicotinic cholinergic receptor gene in families with schizophrenia, suggesting that deficits in P50 suppression are trait markers for gating abnormalities in schizophrenia spectrum subjects.
|
10618013 |
2000 |
|
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Deficits in gating of the P50 response have been shown to segregate with schizophrenia in this sample and may identify carriers of gene(s) predisposing for schizophrenia.
|
8094267 |
1993 |
|
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diminished gating of the P50 auditory evoked response to repeated stimuli is a psychophysiological feature of schizophrenia, that is also present in many relatives of patients.
|
1450287 |
1992 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diminished suppression of the P50 auditory evoked potential is a phenotype used in studies of genetic susceptibility in schizophrenia.
|
15625200 |
2005 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
DMXBA is well tolerated in humans and a new study in persons with schizophrenia has found that DMXBA enhances both P50 auditory gating and cognition. alpha7 Nicotinic acetylcholine receptor agonists appear to be viable candidates for the treatment of cognitive disturbances in schizophrenia.
|
17349863 |
2007 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evidence of normalized auditory P50 suppression with acute nicotine in schizophrenia has supported the contention that elevated smoking rates in this disorder may be an attempt to correct a nicotinic receptor pathophysiology that may underly impaired sensory gating in these patients.
|
19961902 |
2010 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Following reports of SG improvements in low P50 suppressing SCZ patients and healthy participants with the α7 agonist, CDP-choline, this pilot study examined the combined modulatory effect of CDP-choline (500 mg) and galantamine (16 mg), a nAChR positive allosteric modulator and acetylcholinesterase inhibitor, on SG to speech stimuli in twenty-four SCZ patients in a randomized, double-blind and placebo-controlled design.
|
30790597 |
2019 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gating of the theta-alpha-frequency oscillatory signal in the paired-click paradigm is more strongly associated with schizophrenia and has significantly higher heritability compared with the traditional P50 gating.
|
18762587 |
2008 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, the P50 and N100 decrease correlated with the unaffected subjects' genetic resemblance to schizophrenia patients.
|
16876141 |
2006 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast to the Colorado studies in the non-Colorado studies P50 suppression would not qualify as an endophenotype for schizophrenia.
|
17604606 |
2007 |